GW Pharma shares surge on positive PhIII followup; Illumina leads $18M round for Stilla's DNA tech
→ GW Pharma $GWPH already won their big FDA approval to sell Epidiolex for rare seizure cases, setting the groundbreaking cannabinoid drug on track to what many experts will believe will become a blockbuster. So their second round of positive Phase III data in Dravet syndrome can be considered icing on the cake. Both doses of the drug produced statistically significant reductions in convulsive seizures compared to a placebo. The company’s stock surged 4% on the news.
→ Illumina has led an $18 million A round for Paris-based Stilla Technologies, which developed new tech for analyzing DNA mutations. Kurma Partners, LBO France, BNP Paribas Développement, Paris Saclay Seeds and Idinvest Partners all participated.
→ CBT Pharmaceuticals and Zhejiang Bossan Pharmaceutical have agreed to collaborate on a program combining two of their drugs. CBT gains worldwide rights outside of China to develop and commercialize ES-072, Bossan’s novel epidermal growth factor receptor inhibitor, in combination with CBT’s proprietary c-Met inhibitor (CBT-101) and the anti-PD1 antibody (CBT-501).